Purchase this article with an account.
P.A. Brannan, H.K. Anderson, R.C. Kersten, D.R. Kulwin; Squamous Cell Carcinoma in situ of the Eyelid Successfully Treated With Imiquimod . Invest. Ophthalmol. Vis. Sci. 2005;46(13):5401.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: To present a rare case of squamous cell carcinoma in situ (Bowen's disease) affecting the eyelid that was successfully treated with imiquimod.The clinical presentation, histopathology and treatment are presented. The immunomodulatory effects of imiquimod are described in detail. Methods: Chart review Results:Biopsy proven squamous cell carcinoma in situ only involving the entire left lower eyelid was treated with imiquimod for three months. After treatment, the tumor resolved both clinically and histopathologically. There was no evidence of recurrence six months after treatment cessation. Conclusions:Imiquimod produces indirect antitumor activity by stimulating the cell–mediated immune response and local cytokine production. This represents a novel treatment for periocular tumors and may be safely used on the eyelid. Potential benefits include avoiding extensive periocular tumor excision and reconstruction in patients with squamous cell carcinoma in situ.
This PDF is available to Subscribers Only